**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | ESMO GEP-NETs | **Project Code** | PB4LSS079 |
| **Virtual Project Manager** | Choose an item. | **Clinical Program Manager** | Sanneke Koekkoek |
| **Compliance** | ---------- | **Editor** | Trudy Stoddert |

**Launch Date/Internal Launch Date:**

**Early November 2014**

**Project Type**

Webcast

Downloadable Slides (Separate ACD)

CD/DVD

Email Only

Podcast

Other:\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

4-6 Weeks

**Cross Promotion**

Yes

No

If Yes, List Activities: probably a combined e-blast for all esmo webcasts

**Target Audience**

US  
EX-US

Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By: after symposium

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
  
Content Available by:

October

**CME?**

Yes

No

**CME Posttest Link:**

**Webcast/PDS URL:**

www.prIMEoncology.org/GEP-NETs\_Madrid\_2014Webcast

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title:**

**LIVE MEETING-ASSOCIATED VIRTUAL ACTIVITIES**

1. **[~~Meeting-Associated Downloadable Slides]---VERIFY with Clinical after the meeting to see what presentation are to be included~~**

**~~Downloadable Slides From [Insert Meeting Title]~~**

**~~ACTIVITY FEATURES~~**

~~[Icon] Downloadable Slides~~

~~[Insert screen shot]~~

**~~ACTIVITY OVERVIEW~~**

~~prIME Oncology invites you to view Downloadable Slides from the [title] symposium/meeting [choose one] held in San Diego, California, United States.~~

~~\*\*\*May add a “in conjunction with \_\_\_\_\_\_\_” phrase if this is from a symposium at a congress.~~

**~~PROVIDER~~**

~~This activity is provided by prIME Oncology.~~

**~~[Tab—Insert Disease Topic]~~**

~~Discussant:~~ **~~Name, Degree,~~** ~~Institute, City, State, Country~~

~~Topic: Insert agenda topic~~

~~Learning Objective: Insert presentation-specific objective~~

~~[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_~~

~~Discussant:~~ **~~Name, Degree,~~** ~~Institute, City, State, Country~~

~~Topic: Insert agenda topic~~

~~Learning Objective: Insert presentation-specific objective~~

~~[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_~~

~~Discussant:~~ **~~Name, Degree,~~** ~~Institute, City, State, Country~~

~~Topic: Insert agenda topic~~

~~Learning Objective: Insert presentation-specific objective~~

~~[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_~~

~~Discussant:~~ **~~Name, Degree,~~** ~~Institute, City, State, Country~~

~~Topic: Insert agenda topic~~

~~Learning Objective: Insert presentation-specific objective~~

~~[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_~~

1. **[Meeting-Associated Webcast]---VERIFY with Clinical after the meeting to see what presentation are to be included**

**Beyond Symptom Control: Continued Advances in Targeting Gastroenteropancreatic Neuroendocrine Tumors**

**ACTIVITY FEATURES**

[Icon] Interactive Presentation

[Icon] Downloadable Slides

[Icon] CME-Certified (if appropriate)

**ACTIVITY OVERVIEW**

This CME-certified Webcast contains **video and downloadable slides** from the symposium *Beyond Symptom Control: Continued Advances in Targeting Gastroenteropancreatic Neuroendocrine Tumors,* a prIME Oncology educational activity that was held at the 2014 ESMO Congress in Madrid, Spain on 26 September.

**TOPICS**

How much do you know about gastroenteropancreatic neuroendocrine tumors (GEP-NETs)? Test your knowledge

*Jaume Capdevila, MD*

GEP-NETs: A closer look at the characteristics of these diverse tumors

*Ulrich-Frank Pape, MD*

New directions in the treatment of GEP-NETs: Shifting from symptom management to targeting tumors

*Matthias Weber, MD*

Clinical scenario #1—Advanced, grade 2 neuroendocrine tumor in the midgut: Watch and wait or initiate treatment?

*Jaume Capdevila, MD*

Clinical scenario #2—Exploring treatment options for patients with symptomatic, progressive GEP-NETs

*Ulrich-Frank Pape, MD*

Looking forward: prIME Points™ and expert recommendations

*Jaume Capdevila, MD*

**FACULTY**

**Chair**

Jaume Capdevila, MD

Vall d’Hebron University Hospital

Barcelona, Spain

**Faculty**

Ulrich-Frank Pape, MD

Charité University Hospital

Berlin, Germany

Matthias Weber, MD

Johannes Gutenberg University Mainz

Mainz, Germany

**TARGET AUDIENCE**

This educational activity is designed for medical oncologists, endocrinologists, gastroenterologists, pathologists, and other healthcare providers involved and/or interested in the management of patients with GEP-NETs.

**LEARNING OBJECTIVES**

After successful completion of this educational activity, participants should be able to:

* Describe the clinical characteristics and natural history of GEP-NETs
* Apply the role of multidisciplinary care in the treatment of GEP-NETs
* Evaluate recent data from clinical trials investigating novel treatment approaches for patients with GEP-NETs
* Employ best practices in treatment selection for patients with GEP-NETs based on current treatment recommendations and emerging data
* Identify appropriate strategies to minimize disease symptoms and treatment-related adverse events to optimize quality of life in patients with GEP-NETs

[check with Clinical to see if any need to be deleted]

**CONTINUING MEDICAL EDUCATION [if applicable]**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduringactivity for a maximum of 1.5 *AMA PRA Category 1 Credits™.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**METHOD OF PARTICIPATION [if applicable]**

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use.](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx)

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

**DISCLOSURES [if applicable]**

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

**PROVIDER**

This activity is provided by prIME Oncology.

**SUPPORTER**

This educational activity is supported by a grant from IPSEN.

**ACTIVITY DATE**

Release Date: 3 November 2014

Expiration Date: 3 November 2015

**MOBILE APP VIEW ACTIVITY TEXT PER VIDEO**Insert presentation-specific text for the “View Activity” action item on the mobile app.

1. **Web Activity Page Titles**

Landing Page Title:   
Activity Page Title:

1. **Meta Description  
   (One description for each page (including landing pages and all activity pages.**

Downloadable slide presentations from thought leaders in the field in the management of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

1. **Key Words and Key Phrases  
   (Please included as many key words or phrases as are associated with the activity. 15 or more is ideal. These are words or phrases that a viewer might use in a web search. Please add one key word/phrase per line) Example:***gastroenteropancreatic neuroendocrine tumors  
   GEP-NETs  
   neuroendocrine tumors  
   gastroenteropancreatic*

*Matthias Weber  
Jaume Capdevila*

Ulrich-Frank Pape

prIME Points

Multidisciplinary care

Lanreotide

Octreotide LAN

sunitinib

1. **~~[Meeting-Associated Podcast]---VERIFY with Clinical after the meeting to see what presentation are to be included~~**

~~For each presentation:~~

~~Listing: City—Disease—Presenter~~

~~Description: [Name, degree(s)], from [Institution] discusses [insert topic description].~~